X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Sun Pharma with Fulford India - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUN PHARMA vs FULFORD INDIA - Comparison Results

SUN PHARMA    Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

FULFORD INDIA 
   Change

Fulford (India) Limited is an Indian affiliate of Schering-Plough Corporation, USA. The company has presence in oncology, virology and cardiovascular segments. In FY06 the topline of the company grew by 15.5% to Rs. 1519 m from Rs. 1279 m in FY05. PA... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUN PHARMA FULFORD INDIA SUN PHARMA/
FULFORD INDIA
 
P/E (TTM) x 15.3 398.8 3.8% View Chart
P/BV x 3.6 6.2 57.9% View Chart
Dividend Yield % 0.2 0.1 251.3%  

Financials

 SUN PHARMA   FULFORD INDIA
EQUITY SHARE DATA
    SUN PHARMA
Mar-16
FULFORD INDIA
Mar-14
SUN PHARMA/
FULFORD INDIA
5-Yr Chart
Click to enlarge
High Rs1,201942 127.5%   
Low Rs706450 157.0%   
Sales per share (Unadj.) Rs117.5691.4 17.0%  
Earnings per share (Unadj.) Rs19.611.5 171.0%  
Cash flow per share (Unadj.) Rs23.815.4 155.0%  
Dividends per share (Unadj.) Rs1.002.00 50.0%  
Dividend yield (eoy) %0.10.3 36.5%  
Book value per share (Unadj.) Rs130.5380.0 34.3%  
Shares outstanding (eoy) m2,406.603.90 61,707.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x8.11.0 806.4%   
Avg P/E ratio x48.760.7 80.1%  
P/CF ratio (eoy) x40.145.3 88.4%  
Price / Book Value ratio x7.31.8 399.0%  
Dividend payout %5.117.4 29.2%   
Avg Mkt Cap Rs m2,294,8132,714 84,542.2%   
No. of employees `00014.70.4 3,321.4%   
Total wages/salary Rs m47,971505 9,499.3%   
Avg. sales/employee Rs Th19,169.86,073.0 315.7%   
Avg. wages/employee Rs Th3,253.01,137.4 286.0%   
Avg. net profit/employee Rs Th3,197.9100.7 3,176.4%   
INCOME DATA
Net Sales Rs m282,6972,696 10,484.2%  
Other income Rs m6,170125 4,920.0%   
Total revenues Rs m288,8672,822 10,237.0%   
Gross profit Rs m83,239-46 -179,394.2%  
Depreciation Rs m10,13515 66,678.9%   
Interest Rs m4,76910 50,198.9%   
Profit before tax Rs m74,50554 137,209.0%   
Minority Interest Rs m-11,1260-   
Prior Period Items Rs m-190-   
Extraordinary Inc (Exp) Rs m-6,8520-   
Tax Rs m9,34910 97,385.4%   
Profit after tax Rs m47,15945 105,501.3%  
Gross profit margin %29.4-1.7 -1,711.1%  
Effective tax rate %12.517.7 71.0%   
Net profit margin %16.71.7 1,006.3%  
BALANCE SHEET DATA
Current assets Rs m308,6461,738 17,755.6%   
Current liabilities Rs m132,477545 24,321.0%   
Net working cap to sales %62.344.3 140.8%  
Current ratio x2.33.2 73.0%  
Inventory Days Days8348 171.1%  
Debtors Days Days884 2,038.4%  
Net fixed assets Rs m133,60612 1,122,739.5%   
Share capital Rs m2,40739 6,170.8%   
"Free" reserves Rs m266,9091,443 18,496.8%   
Net worth Rs m314,0421,482 21,190.4%   
Long term debt Rs m31,1670-   
Total assets Rs m542,1962,077 26,108.5%  
Interest coverage x16.66.7 247.5%   
Debt to equity ratio x0.10-  
Sales to assets ratio x0.51.3 40.2%   
Return on assets %9.62.6 367.0%  
Return on equity %15.03.0 497.9%  
Return on capital %17.84.3 412.3%  
Exports to sales %14.00-   
Imports to sales %3.124.5 12.9%   
Exports (fob) Rs m39,572NA-   
Imports (cif) Rs m8,882659 1,347.3%   
Fx inflow Rs m42,17117 245,180.2%   
Fx outflow Rs m21,583673 3,206.2%   
Net fx Rs m20,588-656 -3,138.7%   
CASH FLOW
From Operations Rs m67,69490 75,215.3%  
From Investments Rs m-44,549105 -42,590.0%  
From Financial Activity Rs m-19,243-14 136,476.6%  
Net Cashflow Rs m3,902181 2,161.5%  

Share Holding

Indian Promoters % 63.7 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 5.1 3.8 135.0%  
FIIs % 23.0 0.1 23,000.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.3 21.2 39.2%  
Shareholders   133,026 4,783 2,781.2%  
Pledged promoter(s) holding % 0.5 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUN PHARMA With:   PFIZER  GSK PHARMA  PANACEA BIOTECH  WYETH LTD  ABBOTT INDIA  

Compare SUN PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Global Markets Remain Volatile Ahead of US Growth Concerns(RoundUp)

Benchmark indices in US corrected marginally by 0.8% during the week. Minutes of Federal Reserve's July meeting are out and the situation looks to be in favor of the emerging markets.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

May 30, 2017

US markets decline while other geographies grow in the quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SUN PHARMA SHARE PRICE


Aug 18, 2017 (Close)

TRACK SUN PHARMA

  • Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SUN PHARMA 8-QTR ANALYSIS

COMPARE SUN PHARMA WITH

MARKET STATS